<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068898</url>
  </required_header>
  <id_info>
    <org_study_id>XS003_CT001</org_study_id>
    <nct_id>NCT02068898</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Comparison of XS003 and Tasigna</brief_title>
  <official_title>A Comparative, Proof of Concept Study, Comprising of a Pilot Phase Bioavailability Study Part and a Randomised, Cross-over Food-effect Study Part of &quot;XS003&quot; and Originator in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XSpray Microparticles</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XSpray Microparticles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess bioavailability of XS003 given as a single oral dose compared to
      Tasigna® given as a single oral dose in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two parts, the first part is composed as a pilot part and compares the
      bioavailability of single oral doses of XS003 compared to Tasigna® given as single oral dose
      in healthy male subjects. The second part is a food-effect part which assesses the food
      effect of a single oral dose of XS003 in healthy male subjects either fed or fasted. The
      study will also evaluate safety and tolerability of XS003 as secondary objectives.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability of Nilotinib</measure>
    <time_frame>3 days</time_frame>
    <description>Pharmacokinetics measured by Area Under the Curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>XS003 Dose-level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XS003 Dose-level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XS003 Dose-level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tasigna</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Marketed capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XS003</intervention_name>
    <arm_group_label>XS003 Dose-level 1</arm_group_label>
    <arm_group_label>XS003 Dose-level 2</arm_group_label>
    <arm_group_label>XS003 Dose-level 3</arm_group_label>
    <other_name>RightSize Nilotinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tasigna</intervention_name>
    <arm_group_label>Tasigna</arm_group_label>
    <other_name>Nilotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  Age 18 to 55 years of age

          -  Body mass index (BMI) of 18.0 to 29.0 kg/m2

          -  Laboratory parameters in normal range

        Exclusion Criteria:

          -  Females

          -  Current smokers and those who have smoked within the last 12 months. A breath carbon
             monoxide reading of greater than 10 ppm at screening.

          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients.

          -  History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal
             disease as judged by the investigator.

          -  Subject has a QTcF&gt;450 ms based on ECG at screening or a history of additional risk
             factors for Torsades de Pointe (e.g. hypokalaemia, hypomagnesemia, a family history of
             long QT syndrome)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XSpray Microparticles</last_name>
    <role>Study Director</role>
    <affiliation>XSpray Microparticles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>November 10, 2014</last_update_submitted>
  <last_update_submitted_qc>November 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

